ExpreS2ion’s Board, CEO and CFO commit to full exercise of their series TO 8 warrants
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 13 September 2023 - ExpreS2ion Biotech Holding AB's ("ExpreS2ion" or the "Company") announces that the full Board of Directors, as well as its CEO and CFO, have individually committed to exercise all of their series TO